Return to study ST000138 main page
MB Sample ID: SA007695
| Local Sample ID: | PF0028 |
| Subject ID: | SU000157 |
| Subject Type: | Human |
| Subject Species: | Homo sapiens |
| Taxonomy ID: | 9606 |
| Human Inclusion Criteria: | Participants with a baseline fasting glucose < 100 mg/dl and a fasting glucose ? 100 mg/dl at the end of atenolol treatment are considered to have developed IFG. Participants with a baseline fasting glucose < 100 mg/dl and a fasting glucose that remained < 100 mg/dl at the end of atenolol treatment are considered to have not developed IFG. |
| Human Exclusion Criteria: | Participants with a fasting glucose ? 100 mg/dl at baseline are excluded from this study. |
| Species Group: | Human |
Select appropriate tab below to view additional metadata details:
Collection:
| Collection ID: | CO000141 |
| Collection Summary: | At baseline and after completion of atenolol treatment, blood samples were collected and spun. Serum and plasma fractions were stored at -80C. 200 uL of plasma were aliquoted for metabolomics analyses. Sample Type: Blood serum Volume Collected: 200 uL |
| Sample Type: | Blood |
